{"transactions":[{"id":4626199,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":4528,"price":1.61,"value":7290.08,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626198,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":114851,"price":1.61,"value":184910.11,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626197,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":1088,"price":1.65,"value":1795.2,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":4528,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626196,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":27612,"price":1.65,"value":45559.8,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":114851,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626158,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":4528,"price":1.61,"value":7290.08,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4626157,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":114851,"price":1.61,"value":184910.11,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4626156,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":1088,"price":1.65,"value":1795.2,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":4528,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4626155,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:29:33.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":27612,"price":1.65,"value":45559.8,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":114851,"source":{"system":"sec-edgar","filing":"0001231919-26-001224","document":"form4-09242026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001224/form4-09242026_080923.xml","form_type":"4"}},{"id":4624261,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:39:19.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":1285,"price":1.91,"value":2454.35,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":5616,"source":{"system":"sec-edgar","filing":"0001598549-26-000013","document":"form4-09182026_100915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000013/form4-09182026_100915.xml","form_type":"4"}},{"id":4624260,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:39:19.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":32607,"price":1.91,"value":62279.37,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":142463,"source":{"system":"sec-edgar","filing":"0001598549-26-000013","document":"form4-09182026_100915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000013/form4-09182026_100915.xml","form_type":"4"}},{"id":4624123,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:37:58.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":1285,"price":1.91,"value":2454.35,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":5616,"source":{"system":"sec-edgar","filing":"0001231919-26-001197","document":"form4-09182026_100949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001197/form4-09182026_100949.xml","form_type":"4"}},{"id":4624122,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:37:58.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":32607,"price":1.91,"value":62279.37,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":142463,"source":{"system":"sec-edgar","filing":"0001231919-26-001197","document":"form4-09182026_100949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926001197/form4-09182026_100949.xml","form_type":"4"}},{"id":679756,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":6495,"price":0.32,"value":2078.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and\ninvestment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7850155,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679755,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":46,"price":0.32,"value":14.72,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55208,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679754,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":1159,"price":0.32,"value":370.88,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1400560,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679753,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":57476,"price":0.35,"value":20116.6,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and\ninvestment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7856650,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679752,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":409,"price":0.35,"value":143.15,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55254,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679751,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":10255,"price":0.35,"value":3589.25,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1401719,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679750,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":253080,"price":0.38,"value":96170.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and\ninvestment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7914126,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679749,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1830,"price":0.38,"value":695.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55663,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679748,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":45090,"price":0.38,"value":17134.2,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1411974,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":680029,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":6495,"price":0.32,"value":2078.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7850155,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680028,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":46,"price":0.32,"value":14.72,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":55208,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680027,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":1159,"price":0.32,"value":370.88,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1400560,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680026,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":57476,"price":0.35,"value":20116.6,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7856650,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680025,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":409,"price":0.35,"value":143.15,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":55254,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680024,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":10255,"price":0.35,"value":3589.25,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1401719,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680023,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":253080,"price":0.38,"value":96170.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":7914126,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680022,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1830,"price":0.38,"value":695.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":55663,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":680021,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:57:08.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":45090,"price":0.38,"value":17134.2,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1411974,"source":{"system":"sec-edgar","filing":"0001231919-26-000959","document":"form4-08202026_090856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000123191926000959/form4-08202026_090856.xml","form_type":"4"}},{"id":692987,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-07T21:37:52.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":1090000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1419823,"source":{"system":"sec-edgar","filing":"0001628280-26-054941","document":"wk-form4_1786138670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026054941/wk-form4_1786138670.xml","form_type":"4"}},{"id":819042,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:22:31.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023358","document":"wk-form4_1775168549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023358/wk-form4_1775168549.xml","form_type":"4"}},{"id":819041,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:20:14.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023354","document":"wk-form4_1775168412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023354/wk-form4_1775168412.xml","form_type":"4"}},{"id":819040,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54211,"kind":"person","name":"Charych Deborah H.","position":1,"cik":"0001965700","reported_name":"Charych Deborah H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:17:04.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023349","document":"wk-form4_1775168222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023349/wk-form4_1775168222.xml","form_type":"4"}},{"id":819039,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:13:16.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023343","document":"wk-form4_1775167994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023343/wk-form4_1775167994.xml","form_type":"4"}},{"id":819347,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":21586},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819346,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":21586,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":21586,"derivative":{"exercise_price":0.615,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":21586},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819345,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9013,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning August\n24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested"}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":9013},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819344,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":9013,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning August\n24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested"}],"balance_after":9013,"derivative":{"exercise_price":0.615,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":9013},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819343,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024.  The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.56,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819342,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024.  The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested."}],"balance_after":125000,"derivative":{"exercise_price":0.615,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819341,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-27","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819340,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":650000,"derivative":{"exercise_price":0.615,"expiration_date":"2034-10-27","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819339,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.5,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":12360},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819338,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":12360,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":12360,"derivative":{"exercise_price":0.615,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":12360},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819337,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":11.25,"expiration_date":"2030-08-07","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819336,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":36000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":36000,"derivative":{"exercise_price":0.615,"expiration_date":"2030-08-07","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819335,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819334,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:06:22.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":250000,"derivative":{"exercise_price":0.615,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001628280-26-023337","document":"wk-form4_1775167579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026023337/wk-form4_1775167579.xml","form_type":"4"}},{"id":819873,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.25,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819872,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":12000,"derivative":{"exercise_price":0.615,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819871,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025.  In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025."}],"balance_after":0,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819870,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025.  In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025."}],"balance_after":150000,"derivative":{"exercise_price":0.615,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819869,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-28","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819868,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":200000,"derivative":{"exercise_price":0.615,"expiration_date":"2034-10-28","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819867,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819866,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":7100,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":7100,"derivative":{"exercise_price":0.615,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819865,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.56,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819864,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819863,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17004,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":17004},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819862,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":17004,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":17004,"derivative":{"exercise_price":0.615,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":17004},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819828,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54276,"kind":"person","name":"Grayson Paul A.","position":1,"cik":"0001861554","reported_name":"Grayson Paul A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:15:15.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023346","document":"wk-form4_1775168112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861554/000162828026023346/wk-form4_1775168112.xml","form_type":"4"}},{"id":820198,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.56,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820197,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820196,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7080,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.5,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":7080},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820195,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":7080,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested."}],"balance_after":7080,"derivative":{"exercise_price":0.615,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":7080},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820194,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":11.25,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820193,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested."}],"balance_after":8000,"derivative":{"exercise_price":0.615,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820192,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-29","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820191,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":125000,"derivative":{"exercise_price":0.615,"expiration_date":"2034-10-29","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820190,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22021,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":22021},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820189,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":22021,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":22021,"derivative":{"exercise_price":0.615,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":22021},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820188,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9194,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August\n24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":9194},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820187,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":9194,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August\n24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":9194,"derivative":{"exercise_price":0.615,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":9194},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820186,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":820185,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:07:48.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":150000,"derivative":{"exercise_price":0.615,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-023340","document":"wk-form4_1775167665.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026023340/wk-form4_1775167665.xml","form_type":"4"}},{"id":914146,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T02:06:29.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006631","document":"wk-form4_1770689187.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026006631/wk-form4_1770689187.xml","form_type":"4"}},{"id":914145,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T01:54:50.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006625","document":"wk-form4_1770688487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026006625/wk-form4_1770688487.xml","form_type":"4"}},{"id":914144,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54211,"kind":"person","name":"Charych Deborah H.","position":1,"cik":"0001965700","reported_name":"Charych Deborah H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T01:54:33.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006622","document":"wk-form4_1770688470.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026006622/wk-form4_1770688470.xml","form_type":"4"}},{"id":914143,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T01:54:28.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006621","document":"wk-form4_1770688465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026006621/wk-form4_1770688465.xml","form_type":"4"}},{"id":914298,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T01:54:11.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":280000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001628280-26-006618","document":"wk-form4_1770688448.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000162828026006618/wk-form4_1770688448.xml","form_type":"4"}},{"id":914559,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54276,"kind":"person","name":"Grayson Paul A.","position":1,"cik":"0001861554","reported_name":"Grayson Paul A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:56.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006626","document":"wk-form4_1770688493.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861554/000162828026006626/wk-form4_1770688493.xml","form_type":"4"}},{"id":914595,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:45.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":125000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-006624","document":"wk-form4_1770688482.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000162828026006624/wk-form4_1770688482.xml","form_type":"4"}},{"id":914586,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:39.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":150000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-006623","document":"wk-form4_1770688476.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026006623/wk-form4_1770688476.xml","form_type":"4"}},{"id":914651,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54319,"kind":"person","name":"Diep Tuan Tu","position":1,"cik":"0002013809","reported_name":"Diep Tuan Tu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:23.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":125000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-006620","document":"wk-form4_1770688461.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013809/000162828026006620/wk-form4_1770688461.xml","form_type":"4"}},{"id":914693,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67279,"kind":"person","name":"Arora Puneet S.","position":1,"cik":"0002035933","reported_name":"Arora Puneet S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:17.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":125000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001628280-26-006619","document":"wk-form4_1770688454.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035933/000162828026006619/wk-form4_1770688454.xml","form_type":"4"}},{"id":1057600,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":6470,"price":3.42,"value":22127.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":57493,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1057599,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":163979,"price":3.42,"value":560808.18,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1457064,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1057598,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":2314,"price":3.57,"value":8260.98,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":63963,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1057597,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":58642,"price":3.57,"value":209351.94,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1621043,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1058371,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":6470,"price":3.42,"value":22127.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":57493,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1058370,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":163979,"price":3.42,"value":560808.18,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1457064,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1058369,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":2314,"price":3.57,"value":8260.98,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":63963,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1058368,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":21270,"kind":"organization","name":"5AM Partners VII, LLC","position":1,"cik":"0001873545","reported_name":"5AM Partners VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21271,"kind":"organization","name":"5AM Ventures VII, L.P.","position":2,"cik":"0001844435","reported_name":"5AM Ventures VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21272,"kind":"organization","name":"5AM Partners II, LLC","position":3,"cik":"0001555952","reported_name":"5AM Partners II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21273,"kind":"organization","name":"5AM Ventures II LP","position":4,"cik":"0001386509","reported_name":"5AM Ventures II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21274,"kind":"organization","name":"5AM CO-INVESTORS II LP","position":5,"cik":"0001390376","reported_name":"5AM CO-INVESTORS II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":7,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":8,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:05:36.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":58642,"price":3.57,"value":209351.94,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1621043,"source":{"system":"sec-edgar","filing":"0001415889-25-022806","document":"form4-08222025_110831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873545/000141588925022806/form4-08222025_110831.xml","form_type":"4"}},{"id":1238743,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-28T18:54:45.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":43026,"price":4.99,"value":214699.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary transactions by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade."}],"balance_after":167522,"source":{"system":"sec-edgar","filing":"0001516551-25-000022","document":"wk-form4a_1740786879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655125000022/wk-form4a_1740786879.xml","form_type":"4/A","original_submission_date":"2024-11-19"}},{"id":1238742,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":67270,"kind":"person","name":"ARSENAULT KAITLYN","position":1,"cik":"0001877242","reported_name":"ARSENAULT KAITLYN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-28T18:54:45.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":190,"price":5.55,"value":1054.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary transactions by the Reporting Person."}],"balance_after":210548,"source":{"system":"sec-edgar","filing":"0001516551-25-000022","document":"wk-form4a_1740786879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877242/000151655125000022/wk-form4a_1740786879.xml","form_type":"4/A","original_submission_date":"2024-11-19"}},{"id":1242522,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T00:45:56.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning February 21, 2025."}],"balance_after":35000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001516551-25-000020","document":"wk-form4_1740617150.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000020/wk-form4_1740617150.xml","form_type":"4"}},{"id":1242521,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:51:47.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning February 21, 2025."}],"balance_after":35000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001516551-25-000016","document":"wk-form4_1740610301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000016/wk-form4_1740610301.xml","form_type":"4"}},{"id":1242520,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:45:16.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning February 21, 2025."}],"balance_after":35000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001516551-25-000012","document":"wk-form4_1740609908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000012/wk-form4_1740609908.xml","form_type":"4"}},{"id":1242773,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":25413,"kind":"person","name":"DHILLON PUNIT","position":1,"cik":"0001425052","reported_name":"DHILLON PUNIT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:43:44.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning February 21, 2025."}],"balance_after":250000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001516551-25-000010","document":"wk-form4_1740609817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425052/000151655125000010/wk-form4_1740609817.xml","form_type":"4"}}],"next_cursor":"2025-02-26T22:43:44.000000Z,1242773"}